SCHEMBL629972

SCHEMBL629972

O=C(CCCCCC(=O)N(c1ccccc1)c1ccccc1)N(c1ccccc1)c1ccccc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 2/20 0.61
NPC1 O15118 1/20 0.61
ALDH1A1 P00352 1/20 0.61
POLB P06746 1/20 0.61
HTT P42858 1/20 0.61
RAB9A P51151 1/20 0.61
KMT2A Q03164 1/20 0.61
L3MBTL1 Q9Y468 3/20 0.48
MAPT P10636 2/20 0.48
TDP1 Q9NUW8 2/20 0.48
LMNA P02545 1/20 0.48
TRPM8 Q7Z2W7 1/20 0.46
ALOX5 P09917 5/20 0.46
KDM4A O75164 1/20 0.45
KDM5A P29375 1/20 0.45
KDM4C Q9H3R0 1/20 0.45
PHF8 Q9UPP1 1/20 0.45
KDM2A Q9Y2K7 1/20 0.45
TP53 P04637 1/20 0.44
RXFP1 Q9HBX9 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17131834 1.00 NPSR1 (0.61) NPSR1NPC1ALDH1A1POLBHTT
SCHEMBL6673813 0.98 NPSR1 (0.63) NPSR1NPC1ALDH1A1POLBHTT
SCHEMBL547693 0.94 NPSR1 (0.55) NPSR1NPC1ALDH1A1POLBHTT
SCHEMBL629973 0.94 NPSR1 (0.55) NPSR1NPC1ALDH1A1POLBHTT
SCHEMBL1769746 0.92 NPSR1 (0.53) NPSR1NPC1ALDH1A1POLBHTT
SCHEMBL10596450 0.92 NPSR1 (0.53) NPSR1NPC1ALDH1A1POLBHTT
SCHEMBL18240156 0.91 NPC1 (0.54) NPSR1NPC1ALDH1A1POLBHTT
SCHEMBL7643097 0.91 NPC1 (0.54) NPSR1NPC1ALDH1A1POLBHTT
SCHEMBL18240146 0.91 NPC1 (0.54) NPSR1NPC1ALDH1A1POLBHTT
SCHEMBL12472589 0.91 NPC1 (0.54) NPSR1NPC1ALDH1A1POLBHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 115 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4728051-A1 STANDARDISING PLURIPOTENT STEM CELLS United Kingdom Research and Innovation (GB) 2026-04-22 EP claimed
US-20250144056-A1 ANTIMICROBIAL HOST DEFENSE PEPTIDE-INDUCING COMPOSITIONS AND METHODS OF PRODUCTION AND USE THEREOF BOARD OF REGENTS FOR THE OKLAHOMA AGRICULTURAL AND MECH COLLEGES (US) 2025-05-08 US claimed
WO-2025059442-A1 MODULATING PLANT RESPONSES TO STRESS AND GROWTH WITH CHEMICALS REMOTE EPIGENETICS INC. (US) 2025-03-20 WO claimed
WO-2024256607-A1 STANDARDISING PLURIPOTENT STEM CELLS UNITED KINGDOM RESEARCH AND INNOVATION (GB) 2024-12-19 WO claimed
US-20240398814-A1 KRAS INHIBITOR AND HDAC INHIBITOR COMBINATION FOR THE TREATMENT OF CANCER NORTHWESTERN UNIVERSITY 2024-12-05 US claimed
EP-4410284-A1 COMPOUND AND METHOD FOR THE TREATMENT OF ZELLWEGER SPECTRUM DISORDER Apteeus (FR) 2024-08-07 EP claimed
US-20230265432-A1 METHODS AND COMPOSITIONS FOR TREATING ACUTE MYELOID LEUKEMIA Sanford Burnham Prebys Medical Discovery Institute 2023-08-24 US claimed
WO-2023147573-A2 ANTIMICROBIAL HOST DEFENSE PEPTIDE-INDUCING COMPOSITIONS AND METHODS OF PRODUCTION AND USE THEREOF BOARD OF REGENTS FOR THE OKLAHOMA AGRICULTURAL AND MECHANICAL COLLEGES (US) 2023-08-03 WO claimed
EP-3071040-B2 METHOD FOR SCALABLE SKELETAL MUSCLE LINEAGE SPECIFICATION AND CULTIVATION UNIV MISSOURI (US) 2022-12-28 EP claimed
EP-3390653-B1 IMPROVED RECOMBINANT PRODUCTION METHOD HOFFMANN LA ROCHE (CH) 2022-08-10 EP claimed
US-20200399670-A1 RECOMBINANT PRODUCTION METHOD HOFFMANN-LA ROCHE INC. (US) 2020-12-24 US claimed
US-10745731-B2 Recombinant production method HOFFMANN-LA ROCHE INC. (US) 2020-08-18 US claimed
US-20190002947-A1 RECOMBINANT PRODUCTION METHOD HOFFMANN-LA ROCHE INC. (US) 2019-01-03 US claimed
EP-3390653-A1 IMPROVED RECOMBINANT PRODUCTION METHOD H. Hoffnabb-La Roche Ag (CH) 2018-10-24 EP claimed
WO-2017102908-A1 IMPROVED RECOMBINANT PRODUCTION METHOD F. HOFFMANN-LA ROCHE AG (CH) 2017-06-22 WO claimed
EP-3071040-A1 METHOD FOR SCALABLE SKELETAL MUSCLE LINEAGE SPECIFICATION AND CULTIVATION The Curators of the University of Missouri (US) 2016-09-28 EP claimed
US-20160251625-A1 METHOD FOR SCALABLE SKELETAL MUSCLE LINEAGE SPECIFICATION AND CULTIVATION NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR 2016-09-01 US claimed
US-20160227830-A1 METHOD FOR SCALABLE SKELETAL MUSCLE LINEAGE SPECIFICATION AND CULTIVATION UPSIDE FOODS, INC. 2016-08-11 US claimed
WO-2015066377-A1 METHOD FOR SCALABLE SKELETAL MUSCLE LINEAGE SPECIFICATION AND CULTIVATION THE CURATORS OF THE UNIVERSITY OF MISSOURI (US) 2015-05-07 WO claimed
WO-2014172776-A1 COMPOUNDS FOR THE TREATMENT OF MUCOPOLYSACCHARIDOSES THE HOSPITAL FOR SICK CHILDREN (CA) 2014-10-30 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10745731-B2 Recombinant production method HDAC8, HDAC7, HDAC11 NPSR1 2976/4885NPC1 4422/4885ALDH1A1 4100/4885
US-20200399670-A1 RECOMBINANT PRODUCTION METHOD HDAC8, HDAC7, HDAC11 NPSR1 2976/4885NPC1 4422/4885ALDH1A1 4100/4885
US-20240398814-A1 KRAS INHIBITOR AND HDAC INHIBITOR COMBINATION FOR THE TREATMENT OF CANCER KRAS, HRAS, HDAC1 NPSR1 4781/4885NPC1 2902/4885ALDH1A1 1530/4885
US-20190002947-A1 RECOMBINANT PRODUCTION METHOD HDAC8, HDAC7, HDAC11 NPSR1 2976/4885NPC1 4422/4885ALDH1A1 4100/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.